27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
AstraZeneca plc (NYSE:AZN) second-quarter earnings beat estimates as demand for its therapies centered on diabetes and cancer remained strong, with the drugmaker also working on a potential coronavirus vaccine.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The British drugmaker recorded sales of $6.28 billion and core EPS of $0.96.
Wall Street analysts expected an EPS of $0.44 and sales of $6.28 billion. In the same quarter last year, the drugmaker had reported earnings per share of $0.73 and sales of $5.82 billion.
AstraZeneca said it remained on track to deliver a vaccine and therapies for COVID-19.
The company “has mounted a significant response to COVID-19, with capacity to deliver over two billion doses of AZD1222, the accelerated development of our monoclonal antibodies and new trials for the use of Calquence and Farxiga to treat patients affected by the virus,” CEO Pascal Soirot noted.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
AstraZeneca and partner Oxford University reported positive efficacy for their coronavirus vaccine earlier this month.
Why It Matters
Sale of drugs for diabetes, heart conditions, and cancer, which includes Tagrisso — a lung cancer drug, are putting the pharmaceutical giant on track to profit for the third year in a row in terms of sales, Reuters noted.
The British drug company announced this week it had entered into a $6 billion deal with Japan’s Daiichi Sankyo Company, Limited (OTC:DSNKY) to treat multiple types of tumors.
Price Action
AstraZeneca shares traded 2.8% higher at $58.25 in the pre-market session Thursday.
Photo courtesy: AstraZeneca
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.